Mucinous ovarian cancer: lines of therapy
2 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Early stage | Unilateral salpingo-oophorectomy or hysterectomy with staging; appendicectomy if abnormal; chemotherapy usually omitted for stage IA and IB. | - |
Second line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Advanced or recurrent | Cytoreduction; carboplatin-paclitaxel or gastrointestinal-type capecitabine-oxaliplatin; trastuzumab for HER2-amplified tumours in trials. | 89 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.